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Abstract
Background: The study of lipid metabolism in stem cell physiology has recently raised great interest. The role of lipids
goes beyond the mere structural involvement in assembling extra- and intra-cellular compartments. Nevertheless, we
are still far from understanding the impact of membrane lipidomics in stemness maintenance and differentiation patterns.
In the last years, it has been reported how in vitro cell culturing can modify membrane lipidomics. The aim of the present
work was to study the membrane fatty acid profile of mesenchymal stromal cells (MSCs) derived from human
fetal membranes (hFM-MSCs) and to correlate this to specific biological properties by using chemically defined tailored
lipid supplements (Refeed®).
Methods: Freshly isolated hFM-MSCs were characterized for their membrane fatty acid composition. hFM-MSCs
were cultivated in vitro following a classical protocol and their membrane fatty acid profile at different passages was
compared to the profile in vivo. A tailored Refeed® lipid supplement was developed with the aim of reducing the
differences created by the in vitro cultivation and was tested on cultured hFM-MSCs. Cell morphology, viability,
proliferation, angiogenic differentiation, and immunomodulatory properties after in vitro exposure to the tailored
Refeed® lipid supplement were investigated.
Results: A significant modification of hFM-MSC membrane fatty acid composition occurred during in vitro culture.
Using a tailored lipid supplement, the fatty acid composition of cultured cells remained more similar to their in vivo
counterparts, being characterized by a higher polyunsaturated and omega-6 fatty acid content. These changes in
membrane composition had no effect on cell morphology and viability, but were linked with increased cell proliferation
rate, angiogenic differentiation, and immunomodulatory properties. In particular, Refeed®-supplemented hFM-MSCs
showed greater ability to express fully functional cell membrane molecules.
Conclusions: Culturing hFM-MSCs alters their fatty acid composition. A tailored lipid supplement is able to improve in
vitro hFM-MSC functional properties by recreating a membrane environment more similar to the physiological
counterpart. This approach should be considered in cell therapy applications in order to maintain a higher cell quality
during in vitro passaging and to influence the outcome of cell-based therapeutic approaches when cells are
administered to patients.
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Background
In regenerative medicine, high therapeutic promises have
been based on the possibility of stimulating ex vivo and in
vitro expansion of stem cells and their differentiation into
functional progeny that could regenerate injured tissues/
organs in humans [1, 2]. Alterations in cell properties may
occur during in vitro manipulation due to biochemical or
biophysical changes from in vivo physiological conditions
to in vitro ones [3, 4]. Without proper culture systems and
protocols stem cells cannot grow normally outside the
body and will gradually lose their multipotency or pluripo-
tency (i.e., they will differentiate), and can undergo early
senescence [5, 6]. Substrate surface chemistry and culture
medium composition are the two main factors that re-
searchers have spent a long time trying to optimize for in
vitro cell culture [7]. The development of a fully defined
and xeno-free system (i.e., chemically and physically de-
fined) is required in stem/somatic cell culture to provide a
“non-contaminated” cell population for cell therapy and
tissue regeneration to eliminate safety concerns related to
clinical use.
In this context, lipid metabolism is pivotal in stem cell
physiology and it plays a central role in stem cell main-
tenance and differentiation [8–10]. However, the full un-
derstanding of stem cell lipid metabolism is still far
away, but once achieved it could bring great advances in
their handling and use. Kang and co-workers recently
reviewed the preliminary efforts produced by the stem
cell community in investigating the in vitro regulation of
stem cell proliferation and differentiation by essential
fatty acids and their metabolites [11].
Among stem cell populations, mesenchymal stromal
cells (MSCs) draw the attention of the scientific commu-
nity for their widespread properties, functions, and clinical
applications [12, 13]. One of the most promising functions
revolves around their interaction with the immune system,
modifying its response [14, 15]. MSCs can be isolated
from several fetal, perinatal, and adult tissues [16].
Placenta-derived tissues (i.e., placenta, fetal membrane,
and umbilical cord) are interesting sources of MSCs for
research purposes and clinical applications due to their
readily availability and easy recovery without any ethical
concerns [17]. These perinatal cells are able to proliferate
in vitro for several passages [18] and present the classical
MSC immunophenotype (CD44+, CD90+, CD73+, CD14–,
CD31–, CD34–, CD45–) [19]. They can differentiate
through the three classical mesodermal lineages (osteo-
genic, chondrogenic, and adipogenic) [20–22] and also
into endothelial [23], hepatocytic [24], and myogenic [25]
lineages, but present differences depending on the origin
of the cells. Moreover, placenta-derived stromal cells have
been demonstrated to preserve their plasticity alongside
the maintenance of fetal tolerance due to their immuno-
modulatory properties [26–28].
These two biological characteristics could be useful for
promising cell therapy approaches in regenerative medi-
cine. Moreover, mesenchymal cells isolated from human
placenta have been demonstrated to treat ischemia in an
animal model [29] and reduce inflammation in pre-
eclampsia-like features during pregnancy in an animal
model [30]. The in vivo characteristics and properties of
MSCs should be preserved in vitro in order to study and
more effectively utilize MSCs.
Similar to the other typologies of stem cells, MSCs show
a clear preference for ATP production through glycolysis,
rather than by using glucose and fatty acid oxidation [31].
To date, only a few studies on MSC membrane lipids have
been performed [32, 33], and membrane lipid composition
during in vitro expansion of MSCs has not been studied
systematically. Changes in the membrane fatty acid profile
during MSC differentiation [34–36] and results obtained
by lipid supplementation [37] show how membrane lipids
play a crucial role in MSC metabolism, even if this is still
mainly unexplored.
As shown elsewhere [38], an adequate integrative lipid
supplementation is fundamental to improving the quality
of in vitro cells and to modulate specific cellular proper-
ties of interest. In fact, in the majority of cases, cultured
cells develop a membrane network that is altered and
non-functional to their physiology, thus reducing their
full potential.
In this work, we investigated how the membrane fatty
acid composition of MSCs derived from human fetal
membranes (hFM-MSCs) is modified by the in vitro
culturing process. We showed that a tailored lipid sup-
plement is able to maintain in vitro a membrane lipid
pattern more similar to the physiological one. Finally, we
explored how membrane lipid changes are able to
impact on many relevant biological properties of in vitro
hFM-MSCs and discuss potential implications of lipid
monitoring and supplementation in cell therapy applica-
tions and related therapeutic approaches.
Methods
Isolation and cultivation of fetal membrane mesenchymal
stromal cells
Term placentas were obtained by cesarean section from
healthy donor mothers, after written informed consent
and according to the policy of the local ethical committee.
The study was approved by the local ethical committee
(St. Orsola-Malpighi University Hospital Ethical Committee,
protocol number 1645/2014, ref. 35/2014/U/Tess).
Fetal membrane samples were separated from the
chorionic plate and washed in phosphate-buffered saline
(PBS; Lonza, Walkersville, MD, USA) containing 1%
penicillin-streptomycin solution (Lonza, Walkersville,
MD, USA). For hFM-MSC isolation, small fragments of
membranes were minced and then digested using a
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solution of 1 mg/ml collagenase type IV (Sigma-Aldrich
Co., St. Louis, MO, USA) and 0.25% trypsin-EDTA
(Lonza, Walkersville, MD, USA). The fragments were
resuspended for 15 min, and then incubated for 15 min at
37 °C twice. Fetal bovine serum (FBS; Lonza, Walkersville,
MD, USA) was added and a final centrifugation at 400 g
for 10 min was performed. The pellet was resuspended
and cells were plated in culture flasks in DMEM with
high glucose (Lonza, Walkersville, MD, USA) and
supplemented with 10% FBS, 2 mM L-glutamine and
1% penicillin-streptomycin solution.
Membrane isolation following culture
Cells (7 × 106) were collected in a 15-ml tube, centrifuged
at 500 g for 5 min, and resuspended in 10 ml PBS. The
wash was repeated five times in order to remove traces of
medium and serum used during the culture process. Cells
were then resuspended into 500 μl PBS and collected in a
1-ml tube, to which 500 μl sterile H2O were added. Cells
were then centrifuged for 30 min at 15,000 g in a refriger-
ated centrifuge at 4 °C. The collected membranes were
resuspended in 1 ml PBS:H2O (1:1) and washed five times
following the same procedure.
Fatty acid composition analysis
Cell membrane lipids were extracted with CHCl3/MeOH
(2:1 vol/vol) and then incubated with 0.5 M KOH in
methanol for 10 min at room temperature, thus trans-
esterifying fatty acids linked by ester bonds to methanol
to form fatty acid methyl esters (FAMEs). FAMEs were
extracted with n-hexane and separated by gas chroma-
tography in an Agilent 7820A GC System (Agilent
Technologies, Santa Clara, USA) fitted with a 60 m ×
0.32 mm DB23 capillary column, film thickness 0.25 μm,
and a flame ionization detector (FID). Helium was used
as a carrier gas at 2.54 ml/min and the spilt injector was
used with a split ratio of 10:1. Injector temperature was
250 °C and detector temperature was 260 °C. The
column oven temperature was maintained at 50 °C for
2 min after sample injection and was programmed for
the following temperature gradient: 10 °C/min from
50 °C to 180 °C, 3 °C/min from 180 °C to 200 °C and
holding at 200 °C for 6 min. The separation was recorded
with G6714AA SW EZChrom Elite Compact (Agilent
Technologies). FAMEs were identified by comparison with
standards purchased from NuCheckPrep Inc. (Elysian,
USA). FAMEs are expressed in weight %, based upon the
precentage contribution of the peak area of each FAME in
the chromatogram. To take into account the different sig-
nal of the detector for different molecules, a correction
factor was applied to the experimental data coming from
the integration of the chromatograms. The total of the
peaks analyzed for each chromatographic run was 100.
Fatty acids are calculated as follows:
X
Saturated Fatty Acids SFAsð Þ
¼ 14 : 0 þ 15 : 0 þ 16 : 0 þ 17 : 0 þ 18 : 0
þ 20 : 0 þ 22 : 0 þ 23 : 0 þ 24 : 0;
X
Monounsaturated Fatty Acids MUFAsð Þ
¼ 16 : 1n−7 þ 18 : 1n−9 þ 18 : 1n−7
þ 20 : 1n−9 þ 22 : 1n−9 þ 24 : 1n−9;
X
Polyunsaturated Fatty Acids PUFAsð Þ
¼ 18 : 2n−6 þ 18 : 3n−6 þ 18 : 3n−3
þ 20 : 3n−9 þ 20 : 3n−6 þ 20 : 4n−6
þ 20 : 3n−3 þ 20 : 5n−3 þ 22 : 2n−6
þ 22 : 4n−6 þ 22 : 5n−6 þ 22 : 5n−3
þ 22 : 6n−3;
X
Omega−3 ¼ 18 : 3n−3 þ 20 : 3n−3
þ 20 : 5n−3 þ 22 : 5n−3 þ 22 : 6n−3;
X
Omega−6 ¼ 18 : 2n−6 þ 18 : 3n−6
þ 20 : 3n−6 þ 20 : 4n−6 þ 22 : 2n−6
þ 22 : 4n−6 þ 22 : 5n−6:
Refeed® supplements
Refeed® supplements (Remembrane Srl, Imola, Italy) are
a completely defined combination of non-animal-derived
lipids and antioxidants (NuCheckPrep Inc., Elysian,
USA; Sigma Aldrich Co., St. Louis, MO, USA; Appli-
chem an ITW Inc., Chicago, USA) solubilized in 1 ml
ethanol (Sigma-Aldrich Co., St. Louis, MO, USA). One
milliliter of Refeed® was diluted in 500 ml complete cell
growth medium, with the resulting ethanol concentra-
tion being <1% (vol/vol) in the final medium. Refeed®
composition is shown in Table 1. Starting from the first
passage (P1), treated cells were supplemented with the
full dose of Refeed®. During passage 0 (P0), the full dose
was divided into three equal doses and supplemented at
different times in order to allow cells to adapt to the
supplement.
Immunofluorescence
Cells were seeded (2.5 × 104) onto glass coverslips and
fixed for 10 min in 2% paraformaldehyde at room
Table 1 Composition of Refeed® used for in vitro supplementation




Data are shown as the amount (mg) per 500 ml complete medium
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termperature. After three washes in PBS, cells were
permeabilized for 10 min with PBS 1% Triton (Triton
X-100; Sigma-Aldrich, Co., St. Louis, MO, USA), then
incubated in blocking solution 1× PBS 1% bovine serum
albumin (BSA; Sigma-Aldrich, Co., St. Louis, MO, USA)
for 30 min. Primary antibody anti-Vinculin (1:100; Che-
micon, Temecula, CA, USA) diluted in blocking solution
was added and incubated for 1 h at room temperature.
After three washes in 1× PBS, secondary antibody anti-
mouse Cy3 (1:100; Sigma-Aldrich, Co., St. Louis, MO,
USA) was added diluted in blocking solution and incu-
bated for 45 min at room temperature. Cortical actin
was stained using FITC-Phalloidin (1:250; Sigma-
Aldrich, Co., St. Louis, MO, USA) and added directly
during secondary antibody incubation. Coverslips were
mounted after washes in PBS in ProLong Gold Antifade
Mountant with Dapi (Thermo Fisher Scientific, Monza,
MB, Italy).
Cell proliferation
hFM-MSCs from passages 1 to 8 were analyzed for their
population doubling, population doubling time, and cu-
mulative population doubling. Cells were seeded at an
initial concentration of 5000 cells/cm2 in T25 culture
flasks. At every passage, cells were harvested with 0.25%
trypsin-EDTA solution for 3 min at 37 °C and counted
with a hemocytometer by erythrosine B exclusion.
Flow cytometry characterization
hFM-MSCs at the third passage were analyzed by flow
cytometry (Attune NxT Flow Cytometer, Thermo Fisher
Scientific) to verify their immunophenotypic profile. The
antibodies used were: for hematopoietic markers (anti-
CD14-allophycocyanin (APC), anti-CD34-fluorescein
isothiocyanate (FITC) (Becton Dickinson), and anti-
CD45-peridinin chlorophyll protein complex (PerCP)
(Becton Dickinson)); for an endothelial-perivascular marker
(anti-CD31-phycoerythrin (PE) (Becton Dickinson)); for
stromal markers (anti-CD44-FITC (Biolegend), anti-CD73-
PE (Becton Dickinson) and anti-CD90-PE (Biolegend)); and
for the major histocompatibility complex class II (anti-
HLA-DR-PE (Becton Dickinson)).
Angiogenic differentiation
In order to induce cells through the angiogenic lineage
they were cultured with and without Refeed® in DMEM
containing 2% FBS with the addition of 50 ng/ml vascu-
lar endothelial growth factor (VEGF; Sigma-Aldrich Co.,
St. Louis, MO, USA) for 6 days, changing the medium
every 2 days. As a negative control of angiogenesis, cells
with and without Refeed® were cultured in standard
medium (DMEM with 10% FBS). Then cells were fixed
for flow cytometric analysis and the expression of FLT1
(VEGFR1; R&D system), KDR (VEGFR2), and von Will-
ebrand factor (vWF; Abcam) was measured.
Immunomodulation
In order to investigate the immunomodulatory proper-
ties of hFM-MSCs on activated peripheral blood mono-
nuclear cells (PBMCs), they were plated in six-well
plates at a density of 10,000 cells/cm2 and allowed to
stabilize in culture for 1 day. PBMCs were isolated from
the blood of healthy donors by density gradient centrifu-
gation (Ficoll-Paque, Sigma-Aldrich) and co-cultured on
hFM-MSC monolayers at a ratio of 10:1 in RPMI with
10% FBS (Lonza, Walkersville, MD, USA). PBMCs were
activated by addition of phytohemagglutinin (PHA;
1 μg/ml; Sigma-Aldrich Co., St. Louis, MO, USA) and
incubated for 72 h at 37 °C and 5% CO2. The negative
control was PBMCs without PHA stimulation and the
positive control consisted of PBMCs stimulated by PHA
in the absence of hFM-MSCs. The immunomodulatory
ability of hFM-MSCs was quantified by BrdU incorpor-
ation by activated PBMCs. After 72 h of co-culture
between hFM-MSCs and PBMCs, the latter were recov-
ered and seeded in a 96-well plate and then BrdU
incorporation levels were quantified using a colorimetric
immunoassay, according to the manufacturer’s instruc-
tions (Cell Proliferation ELISA, BrdU colorimetric kit,
Roche, Basel, Switzerland). hFM-MSCs cultured with
and without activated PBMCs were fixed for flow cyto-
metric analysis. Finally, HLA-G (Abcam ab7904) expres-
sion of hFM-MSCs was measured to confirm the
immunomodulatory phenotype.
Statistical analysis
All the experiments were performed at least three times.
Data are presented as means ± standard deviation and
were analyzed by one and two-way ANOVA or t test
using Graph Pad Prism software. The significance
threshold was p < 0.05.
Results
Cultured hFM-MSCs have significantly different mem-
brane fatty acid composition compared to their fresh un-
cultured counterparts
Fresh uncultured hFM-MSCs showed variability in their
membrane fatty acid composition, likely due to the gen-
etic and lifestyle diversity of the donors. They had a
membrane fatty acid composition mainly characterized
by a high omega-6 fatty acid content, which represented
more than 25% of total membrane fatty acids. The effect
of culturing human hFM-MSCs in the traditional
medium (DMEM+ 10% FBS) on their membrane fatty
acid composition was investigated and results are shown
in Fig. 1. Data clearly demonstrate that significant differ-
ences arise during the first in vitro passages (mainly P0
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and P1) between the membrane fatty acid profiles of in
vitro cultivated hFM-MSCs and those of the correspond-
ing fresh uncultured hFM-MSCs, considering both fatty
acid sums (Fig. 1) and individual fatty acids (data not
shown). Overall, cultured cells had lower proportions of
polyunsaturated fatty acids (PUFAs) than freshly isolated
cells. In particular, they showed a large drop in omega-6
fatty acids, counterbalanced by a marked increase in
MUFA and omega-3 fatty acids (Fig. 1).
Refeed® supplementation partially realigns hFM-MSC
membrane fatty acid composition to that of their fresh
uncultured counterparts
hFM-MSCs were cultured in the traditional medium
(DMEM+ 10% FBS) supplemented with specific Refeed®
supplements, which are completely defined combina-
tions of lipids and lipophilic antioxidants in ethanol (see
Methods). Ethanol and antioxidants did not show any
effect on cultured hFM-MSCs when tested as a negative
control (data not shown). Culture with a tailored Refeed®
formulation was able to partly prevent the changes
induced by the traditional in vitro culture system and to
restore the membrane fatty acid profile over time to one
that better matched that of fresh uncultured hFM-MSCs
(Fig. 1). In particular, Refeed® supplementation was able
to partly reduce the loss of PUFA and omega-6 fatty
acids in particular, while decreasing the accumulation of
MUFA and omega-3 fatty acids. Individual fatty acids
followed the same fluctuations (data not shown). There-
fore, the membrane network of Refeed® supplemented
hFM-MSCs better mimics that of fresh uncultured hFM-
MSCs in its fatty acid composition and so most likely in
its biophysical and functional properties.
Isolation and proliferation
In order to evaluate the effect of Refeed® on cultured
hFM-MSCs, cells were isolated and cultured in vitro
with and without supplementation until passage eight
(P8). Cells cultured with Refeed® showed a morphology
similar to control cells, without lipid accumulation
despite supplementation (Fig. 2a and b). In order to in-
vestigate also the cytoskeleton structure and the cell
adhesion, in particular the focal adhesion complexes, an
immunofluorescence for phalloidin and vinculin was
Fig. 1 Partially preserved cultured hFM-MSC membrane fatty acid
profile after Refeed® lipid supplementation. The main fatty acid
parameters characterizing the membrane fatty acid profile of
fresh uncultured hFM-MSCs (ISO), and how they are modified
during normal (Ctrl) and Refeed®-supplemented in vitro culturing
at different passages (P0, P1, P2, P4, P6, P8). Data are expressed in
weight % of total membrane fatty acids and presented as means ± SD
(n= 8 for ISO, n= 5 for in vitro cultivated hFM-MSCs). FA fatty acid, MUFA
mono-unsaturated fatty acid, n-3 FA omega-3 fatty acid, n-6 FA omega-6
fatty acid, PUFA polyunsaturated fatty acid, SFA saturated fatty acid
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performed. Cells cultured with Refeed® showed no
changes to the cytoskeleton structure nor to the adhesion
complex distribution compared to control cells (Fig. 2c
and d). At each passage, cells were counted and popula-
tion doubling, population doubling time, and cumulative
population doubling were calculated. Figure 3 represents
the theoretical number of cells obtained from initial cell
seeding, valuated at cumulative population doubling
obtained for each passage from 1 to 8. The increase in cell
number, reflecting the rate of proliferation, was greater for
cells cultured with Refeed® (Fig. 3).
Immunophenotypic analysis
Cell surface antigens were assessed by flow cytometry
analysis for a variety of markers associated with
hematopoietic (CD14, CD34, and CD45), mesenchymal
stromal (CD44, CD73, and CD90), and mature endo-
thelial (CD31) cells. Finally, the major histocompati-
bility complex class II HLA-DR was also analyzed.
Figure 4 shows that cells expanded for three passages
in culture with Refeed® supplementation exhibited a
similar immunophenotype to cells cultured in normal
conditions, with high expression of stromal markers,
and low expression of hematopoietic, endothelial
markers, and HLA-DR.
Angiogenic differentiation
In order to understand the biological and functional
effect of Refeed® we studied angiogenic differentiation in
detail. Cells were induced for 6 days with VEGF and
then fixed and analyzed by a flow cytometry procedure
for the expression of FLT1, KDR, and vWF. As shown in
Fig. 5, there was a clear increase of both VEGF receptors
(FLT1 and KDR) and of the typical endothelial cell
marker vWF expression in Refeed® supplemented cells
after angiogenic stimulus.
Fig. 2 Unchanged hFM-MSC morphology after Refeed® lipid supplementation. Light microscopy images of expanded hFM-MSCs cultured in traditional
medium (a; Ctrl) and with Refeed® supplementation (b). Immunofluorescence images for the cytoskeleton marker (phalloidin, green) and focal adhesion
complexes (vinculin, red) of hFM-MSCs cultured in traditional medium (c) and with Refeed® supplementation (d). Nuclei were stained with Dapi (blue)
Fig. 3 Increased hFM-MSC growth kinetics after Refeed® lipid
supplementation. Theoretical in vitro expansion of hFM-MSCs.
The number of cells was obtained considering the initial cell
seeding (5000 cells/cm2) and the related cumulative population
doubling. Control cells (Ctrl) are presented as black squares and cells
supplemented with Refeed® as white squares
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Immunomodulation
Another important aspect of MSCs for clinical applica-
tion is their ability to suppress the immune system. A
co-culture of hFM-MSCs and PHA-activated PBMCs
was performed and, after 3 days, BrdU incorporation
and PBMC cell cycle were analyzed. Figure 6a shows
how Refeed® supplementation increased the ability of
hFM-MSCs to inhibit PBMC proliferation in vitro. In
particular, activated PBMCs show a significantly lower
BrdU incorporation when co-cultured with hFM-MSCs
maintained in culture medium supplemented with
Refeed® (43.27 ± 11.55%) compared to when they were
cultured in standard conditions (75.25 ± 7.02%). These
results suggest that hFM-MSCs have an immunomodu-
latory effect on stimulated PBMCs mediated by lympho-
proliferative inhibition and that this effect is increased
when cells are supplemented with Refeed®.
To support these data, we also analyzed the effect of
Refeed® supplementation on the expression of HLA-G,
one of the possible mediators of the effect previously
described. In cells cultured in standard medium, HLA-G
expression increased from 34.6 ± 4.1 to 55.9 ± 2.6% after
co-culture with PHA-activated PBMCs whereas, in
FM-MSCs supplemented with Refeed®, it increased from
46.2% ± 15.6 to 75.9 ± 10.7% after co-culture with
PHA-activated PBMCs. Figure 6b shows that HLA-G
Fig. 4 Unchanged hFM-MSC immunophenotype after Refeed® lipid supplementation. Representative flow cytometry analysis of mesenchymal
(CD44, CD73, CD90), hematopoietic (CD14, CD34, CD45), and endothelial (CD31) markers, and major histocompatibility complex class II (HLA-DR).
Unstained controls are presented as filled black histograms, the specific cell markers as grey histograms. Ctrl traditional medium
Fig. 5 Improved hFM-MSC angiogenic differentiation after Refeed® lipid supplementation. Cells were induced with VEGF without (Ctrl) and with
Refeed® supplementation. Representative flow cytometry analysis of the VEGF receptors FLT1 and KDR, and von Willebrand factor (vWF). Control
cells are presented as black histograms and induced cells as white histograms
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expression on hFM-MSCs increases in co-culture with
PBMCs and that the increase is greater in Refeed®-sup-
plemented hFM-MSCs.
Discussion
Membrane lipidomics is emerging as a core research
field in stem cell biology [8–10]. Membrane lipids,
including the fatty acid constituents, regulate many
important aspects of stem cell physiology, stemness, and
differentiation [11], although we are a long way from
understanding the complete picture. In vitro culture
conditions are considered important for generating safe
and effective stem cells for clinical use in humans [5, 6].
However, current in vitro conditions for the culture of
stem cells are still far from being optimized and much
more needs to be done to achieve fully efficient in vitro
cultivation processes in order for stem cells to be used in
large-scale industrial processes of cell therapy and regen-
erative medicine applications [5, 6]. In this context,
membrane lipidomics has not yet been considered as a
key factor, and judicious lipid supplementation of in
vitro stem cell cultures is limited and poorly thought
out. This most likely reduces the potential of stem
cell-based therapies.
Providing fatty acids to cultured cells is known to alter
the fatty acid composition of their cell membrane and
this is associated with changes in cell function [37, 38].
However, such effects are poorly studied and defined in
stem cells. To investigate the impact that tailored lipid
supplements, and thus different membrane lipidomics,
could have on stem cells, we have chosen to study hFM-
MSCs (perinatal cells derived from placental tissues) that
Fig. 6 hFM-MSC enhanced immunosuppressive effect on activated peripheral blood mononuclear cells after Refeed® lipid supplementation. a Analysis
of the BrdU incorporation into peripheral blood mononuclear cells (PBMCs) after co-culture with human fetal membrance mesenchymal stromal cells
(hFM-MSCs) with and without Refeed® supplementation. Data are expressed as percentage of BrdU incorporation and presented as means ± SD (n = 3;
***P < 0.05). b Representative flow cytometry analysis of HLA-G expression on hFM-MSCs. Control cells are presented as black histograms and co-cultured
cells as white histograms. Ctrl traditional medium, PHA phytohemagglutinin
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are widely available, easy to recover, and raise no ethical is-
sues [17]. These cells show stem cell-like features, such as
high stemness and wide differentiation potential [20–25].
Moreover, these cells can be cultured in vitro for many
passages and be expanded in sufficient number for clinical
applications [18].
We showed that culture of hFM-MSCs resulted in
marked changes in their fatty acid composition away
from that seen in freshly isolated cells. A striking
decrease in omega-6 fatty acids affected hFM-MSC
membrane composition during the first in vitro passages
(Fig. 1), probably due to the inability of hFM-MSCs to
generate omega-6 fatty acids internally and to the short-
age of omega-6 fatty acids provided by the serum. With
the decrease in membrane fluidity caused by the drop in
omega-6 fatty acid double bonds, cells increased MUFA
synthesis through the upregulation of the Δ9-desaturase
activity, thus lowering SFAs and raising MUFA content in
the membrane system (Fig. 1). MUFAs partially counterba-
lanced the decrease in membrane fluidity, but not in mem-
brane plasticity as they are not able to generate bioactive
lipids as can omega-6 [39].
Furthermore, we identified that a tailored lipid supple-
mentation allows hFM-MSCs to maintain a fatty acid
composition that more closely resembles that of freshly
isolated cells, so preventing membrane changes induced
by in vitro cultivation (Fig. 1). This was associated with
improved biological characteristics of the cultured hFM-
MSCs. For example, the observed increase in hFM-MSC
proliferation, without any morphology or immunopheno-
type alterations, indicates an overall improvement in cell
welfare, probably due to a membrane network with a lipid
composition more similar to that of the corresponding in
vivo cells and to a better metabolism (Figs. 2, 3 and 4).
Increased angiogenic differentiation, documented by
higher expression of a distinctive marker of endothelial
cells (von Willebrand factor) (Fig. 5), is a sign of a
greater cell plasticity, which suggests the likelihood of a
greater efficiency in other differentiation processes. This
is consistent with the higher presence of the two main
receptors involved in angiogenesis (FLT-1 and KDR) in
the plasma membrane of cells treated with Refeed®
(Fig. 5). This suggests that the biological stimulus, in this
case the differentiation stimulus, is more efficiently sup-
ported when the cells have a fatty acid composition
more similar to the one they had in vivo. In addition to
the higher number of these receptors in the membrane,
it is likely that the signaling process also shows greater
efficiency due to an increase in membrane domain
stability provided by a different membrane order [40, 41].
The improvement of the immunomodulatory capacity
of hFM-MSCs seen after culture in the presence of
Refeed® (Fig. 6), albeit small, suggests an improvement
also of the process of protein synthesis, protein folding,
and trafficking, through which the receptors involved
are transferred to the plasma membrane. In addition, a
greater presence of bioactive lipids derived from omega-
6 fatty acids, such as lipoxin A4, could be important in
assuring a more optimal functioning of hFM-MSCs after
culture in the presence of Refeed® [42].
Finally, experiments not reported here indicate a
greater resistance of hFM-MSCs to the freeze/thaw pro-
cesses (data not shown) and a marked improvement in
the isolation efficiency of post-enzymatic digestion of
hFM-MSCs treated with Refeed® (data not shown).
The effects described above originate from specific
ad-hoc lipids that are used by the cell for the creation of a
membrane network with different and more efficient
features than seen if those lipids are not provided to the
cells. A greater presence of PUFAs, particularly of omega-
6 fatty acids, makes the membrane more fluid and more
plastic [39], respectively due to the presence of a greater
number of double bonds (compared with SFAs and
MUFAs) and a greater presence of bioactive lipids.
Greater efficiency in the process of trafficking, transmem-
brane protein folding, and signaling pathways could
contribute to improve the global efficiency of the whole
cell. Another interesting hypothesis comes from recent
work [43] showing that an increase in membrane fluidity
positively affects the solubility and diffusion of oxygen in
membranes, ensuring a greater supply to mitochondria.
This would improve oxidative metabolism.
From the results presented herein, culture of hFM-
MSCs in the presence of the Refeed® lipid supplement
creates in vitro conditions more similar to that seen in
vivo, and contributes to a more efficient cell physiology
and metabolism thus enabling the maintenance of many
cellular responses and functions. It will be important to
conduct a thorough study of the molecular changes that
occur during the culture of these cells and how these
changes are influenced by Refeed®. Among the most intri-
guing future perspectives, there is a possibility of investi-
gating if and how the paracrine activity of these cells
could possibly be influenced by an improved membrane
lipid composition, and whether they could influence in
turn the same or other cell types.
Conclusions
It is now established that membrane lipidomics plays a
fundamental role in cell physiology of stem cells and of
MSCs in particular, although much still remains to be
discovered. In order to achieve intensive use of these
cells in cell therapy and regenerative medicine applica-
tions, it is necessary to make in vitro cultivation
processes more efficient for them to be more suitable for
their large-scale industrial use. It is in this context that
membrane lipidomics and related tailored membrane
lipid supplements can bring important advantages in the
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improvement of both in vitro amplification processes
and the outcome of administering the same to patients,
through an improvement in the quality of the cell and a
realignment to in vivo conditions that enable the expres-
sion of the cells full potential. In this regard, culture of
hFM-MSCs in the presence of the Refeed® lipid supple-
ment creates in vitro conditions more similar to the in
vivo one and contributes to a more efficient cell physi-
ology and metabolism, thus enabling the maintenance of
many cellular responses and functions.
Abbreviations
FAME: Fatty acid methyl ester; FBS: Fetal bovine serum; hFM-MSC: Human
fetal membrane mesenchymal stromal cell; MSC: Mesenchymal stromal cell;
MUFA: Mono-unsaturated fatty acid; PBMC: Peripheral blood mononuclear
cell; PBS: Phosphate-buffered saline; PHA: Phytohemagglutinin;
PUFA: Polyunsaturated fatty acid; SFA: Saturated fatty acid; VEGF: Vascular
endothelial growth factor; vWF: Von Willebrand factor
Acknowledgments
The authors wish to thank Viola Tattini for providing language assistance.
Funding
This study was in part supported by University of Bologna grants (RFO2014).
Availability of data and materials
The datasets generated and/or analyzed during the current study are not
publicly available due to the know-how management policy of Remembrane
srl, but are available from the corresponding author on reasonable request.
Authors’ contributions
AC, PP, MR, and FA conceived and designed the study; MR, CZ, CM, VT, and FR
performed the experiments; PP performed gas chromatography analyses; AC, MR,
FA, and PLT analyzed and interpreted the data; AC, MR, PCC, and LB prepared the
manuscript. All authors have read and approved the final manuscript.
Competing interests
AC and PP are co-founders and shareholders of Remembrane Srl, a manufac-
turer of lipid supplements for use in in vitro culturing. The remaining authors
declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by local ethical committee (St. Orsola-Malpighi University
Hospital Ethical Committee, protocol number 1645/2014, ref. 35/2014/U/Tess).
Written informed consent was obtained from all participants in the study
in accordance with the local ethical committee policy.
Author details
1Remembrane Srl, Imola, Italy. 2Department of Experimental, Diagnostic and
Specialty Medicine, Unit of Histology, Embryology and Applied Biology,
University of Bologna, Via Belmeloro 8, 40126 Bologna, Italy. 3Department of
Morphology, Surgery and Experimental Medicine, Section of Pathology,
Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy.
4Department of Experimental, Diagnostic and Specialty Medicine, Unit of
Nephrology, Dialysis and Renal Transplant, St, Orsola-Malpighi University
Hospital, Via Massarenti 9, 40138 Bologna, Italy. 5Service of
Immunohematology and Transfusion Medicine, St. Orsola-Malpighi University
Hospital, Via Massarenti 9, 40138 Bologna, Italy. 6Laboratory of Molecular
Biology, Institute of Cardiology, Department of Experimental, Diagnostic and
Specialty Medicine, St. Orsola - Malpighi University Hospital, University of
Bologna, Via Massarenti 9, 40138 Bologna, Italy. 7National Institute of
Biostructures and Biosystems at Ettore Sansavini Health Science Foundation
ONLUS - Lab SWITH, Corso Garibaldi 11, 48022 Lugo (RA), Italy. 8Human
Development and Health Academic Unit, Faculty of Medicine, University of
Southampton, Southampton, UK. 9NIHR Southampton Biomedical Research
Centre, University Hospital Southampton NHS Foundation Trust and
University of Southampton, Southampton, UK.
Received: 17 November 2016 Revised: 12 January 2017
Accepted: 21 January 2017
References
1. Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in
therapeutics—recent advances in stem cell biology and their therapeutic
applications in regenerative medicine and cancer therapies. Clin Pharmacol
Ther. 2007;82:252–64.
2. Mimeault M, Batra SK. Concise review: recent advances on the significance
of stem cells in tissue regeneration and cancer therapies. Stem Cells.
2006;24:2319–45.
3. Windmolders S, Willems L, Daniels A, Linsen L, Fanton Y, Hendrikx M, et al.
Clinical-scale in vitro expansion preserves biological characteristics of
cardiac atrial appendage stem cells. Cell Prolif. 2015;48:175–86.
4. Benz K, Stippich C, Freudigmann C, Mollenhauer JA, Aicher WK.
Maintenance of “stem cell” features of cartilage cell sub-populations during
in vitro propagation. J Transl Med. 2013;11:27.
5. Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem
cells: functional changes and implications in stem cell-based therapy. Int J
Mol Sci. 2016;17:1164.
6. Zhu Y, Song X, Wang J, Li Y, Yang Y, Yang T, et al. Placental mesenchymal
stem cells of fetal origin deposit epigenetic alterations during long-term
culture under serum-free condition. Expert Opin Biol Ther. 2015;15:163–80.
7. Wang PY, Thissen H, Kingshott P. Modulation of human multipotent and
pluripotent stem cells using surface nanotopographies and surface-
immobilised bioactive signals: a review. Acta Biomater. 2016;45:31-59.
8. Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, et al. A PML-PPAR-
delta pathway for fatty acid oxidation regulates hematopoietic stem cell
maintenance. Nat Med. 2012;18:1350–8.
9. Yanes O, Clark J, Wong DM, Patti GJ, Sanchez-Ruiz A, Benton HP, et al.
Metabolic oxidation regulates embryonic stem cell differentiation. Nat
Chem Biol. 2010;6:411–7.
10. Knobloch M, Braun SM, Zurkirchen L, von Schoultz C, Zamboni N, Arauzo-
Bravo MJ, et al. Metabolic control of adult neural stem cell activity by Fasn-
dependent lipogenesis. Nature. 2013;493:226–30.
11. Kang JX, Wan JB, He C. Concise review: regulation of stem cell proliferation
and differentiation by essential fatty acids and their metabolites. Stem Cells.
2014;32:1092–8.
12. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem
cells: nature, biology, and potential applications. Stem Cells. 2001;19:180–92.
13. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal
cell function. Stem Cell Res Ther. 2016;7:125.
14. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as
guardians of inflammation. Mol Ther. 2012;20:14–20.
15. Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms
of immunomodulation and therapy. World J Stem Cells. 2014;6:526–39.
16. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et
al. Minimal criteria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement. Cytotherapy.
2006;8:315–7.
17. Evangelista M, Soncini M, Parolini O. Placenta-derived stem cells: new hope
for cell therapy? Cytotechnology. 2008;58:33–42.
18. Parolini O, Alviano F, Bagnara GP, Bilic G, Buhring HJ, Evangelista M, et al.
Concise review: isolation and characterization of cells from human term
placenta: outcome of the first international Workshop on Placenta Derived
Stem Cells. Stem Cells. 2008;26:300–11.
19. Kmiecik G, Niklinska W, Kuc P, Pancewicz-Wojtkiewicz J, Fil D, Karwowska A, et
al. Fetal membranes as a source of stem cells. Adv Med Sci. 2013;58:185–95.
20. Bacenkova D, Rosocha J, Tothova T, Rosocha L, Sarissky M. Isolation and
basic characterization of human term amnion and chorion mesenchymal
stromal cells. Cytotherapy. 2011;13:1047–56.
21. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human
placenta-derived cells have mesenchymal stem/progenitor cell potential.
Stem Cells. 2004;22:649–58.
22. Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall’Ora M, et al. Systemic
delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells
protects from lung and brain metastases. Oncotarget. 2015;6:34774–87.
Chatgilialoglu et al. Stem Cell Research & Therapy  (2017) 8:31 Page 10 of 11
23. Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, et al.
Term amniotic membrane is a high throughput source for multipotent
mesenchymal stem cells with the ability to differentiate into endothelial
cells in vitro. BMC Dev Biol. 2007;7:11.
24. Tamagawa T, Oi S, Ishiwata I, Ishikawa H, Nakamura Y. Differentiation of
mesenchymal cells derived from human amniotic membranes into
hepatocyte-like cells in vitro. Hum Cell. 2007;20:77–84.
25. Ventura C, Cantoni S, Bianchi F, Lionetti V, Cavallini C, Scarlata I, et al.
Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and
endothelial fate in term placenta human mesenchymal stem cells and
enhance cardiac repair in infarcted rat hearts. J Biol Chem. 2007;282:14243–52.
26. Tooi M, Komaki M, Morioka C, Honda I, Iwasaki K, Yokoyama N, et al.
Placenta mesenchymal stem cell derived exosomes confer plasticity on
fibroblasts. J Cell Biochem. 2016;117:1658–70.
27. Liu W, Morschauser A, Zhang X, Lu X, Gleason J, He S, et al. Human
placenta-derived adherent cells induce tolerogenic immune responses. Clin
Transl Immunol. 2014;3:e14.
28. Chen G, Yue A, Ruan Z, Yin Y, Wang R, Ren Y, et al. Comparison of
biological characteristics of mesenchymal stem cells derived from maternal-
origin placenta and Wharton’s jelly. Stem Cell Res Ther. 2015;6:228.
29. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM. The role of
placental-derived adherent stromal cell (PLX-PAD) in the treatment of
critical limb ischemia. Cytotherapy. 2009;11:427–34.
30. Chatterjee P, Chiasson VL, Pinzur L, Raveh S, Abraham E, Jones KA, et al.
Human placenta-derived stromal cells decrease inflammation, placental
injury and blood pressure in hypertensive pregnant mice. Clin Sci (Lond).
2016;130:513–23.
31. Fillmore N, Huqi A, Jaswal JS, Mori J, Paulin R, Haromy A, et al. Effect of fatty
acids on human bone marrow mesenchymal stem cell energy metabolism
and survival. PLoS One. 2015;10:e0120257.
32. Kilpinen L, Tigistu-Sahle F, Oja S, Greco D, Parmar A, Saavalainen P, et al.
Aging bone marrow mesenchymal stromal cells have altered membrane
glycerophospholipid composition and functionality. J Lipid Res.
2013;54:622–35.
33. Campos AM, Maciel E, Moreira AS, Sousa B, Melo T, Domingues P, et al.
Lipidomics of mesenchymal stromal cells: understanding the adaptation of
phospholipid profile in response to pro-inflammatory cytokines. J Cell
Physiol. 2016;231:1024–32.
34. Esmaeli S, Allameh A, Soleimani M, Rahbarizadeh F, Frouzandeh-Moghadam
M. The role of albumin and PPAR-alpha in differentiation-dependent
change of fatty acid profile during differentiation of mesenchymal stem
cells to hepatocyte-like cells. Cell Biochem Funct. 2014;32:410–9.
35. Tao J, Shi J, Lu Y, Dou B, Zhou Z, Gao M, et al. Overexpression of stearoyl-
CoA desaturase 1 in bone-marrow mesenchymal stem cells increases
osteogenesis. Panminerva Med. 2013;55:283–9.
36. Lu Y, Zhou Z, Tao J, Dou B, Gao M, Liu Y. Overexpression of stearoyl-CoA
desaturase 1 in bone marrow mesenchymal stem cells enhance the
expression of induced endothelial cells. Lipids Health Dis. 2014;13:53.
37. Kan I, Melamed E, Offen D, Green P. Docosahexaenoic acid and arachidonic
acid are fundamental supplements for the induction of neuronal
differentiation. J Lipid Res. 2007;48:513–7.
38. Poggi P, Mirabella R, Neri S, Assirelli E, Dolzani P, Mariani E, et al. Membrane
fatty acid heterogeneity of leukocyte classes is altered during in vitro
cultivation but can be restored with ad-hoc lipid supplementation. Lipids
Health Dis. 2015;14:165.
39. Tigistu-Sahle F, Lampinen M, Kilpinen L, Holopainen M, Lehenkari P, Laitinen S,
et al. Metabolism and phospholipid assembly of polyunsaturated fatty acids in
human bone marrow mesenchymal stromal cells. J Lipid Res. 2017;58(1):92-110.
40. Levental KR, Lorent JH, Lin X, Skinkle AD, Surma MA, Stockenbojer EA, et al.
Polyunsaturated lipids regulate membrane domain stability by tuning
membrane order. Biophys J. 2016;110:1800–10.
41. Tisza MJ, Zhao W, Fuentes JS, Prijic S, Chen X, Levental I, et al. Motility and
stem cell properties induced by the epithelial-mesenchymal transition
require destabilization of lipid rafts. Oncotarget. 2016;7:51553–68.
42. Cianci E, Recchiuti A, Trubiani O, Diomede F, Marchisio M, Miscia S, et al.
Human periodontal stem cells release specialized proresolving mediators
and carry immunomodulatory and prohealing properties regulated by
lipoxins. Stem Cells Transl Med. 2016;5:20–32.
43. Moller MN, Li Q, Chinnaraj M, Cheung HC, Lancaster Jr JR, Denicola A.
Solubility and diffusion of oxygen in phospholipid membranes. Biochim
Biophys Acta. 2016;1858:2923–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chatgilialoglu et al. Stem Cell Research & Therapy  (2017) 8:31 Page 11 of 11
